BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough

BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.